Regulus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Regulus Therapeutics's earnings have been declining at an average annual rate of -14.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 59% per year.
Key information
-14.2%
Earnings growth rate
51.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -59.0% |
| Return on equity | -48.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
Sep 28
Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05Revenue & Expenses Breakdown
How Regulus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -42 | 13 | 9 |
| 30 Jun 24 | 0 | -35 | 12 | 0 |
| 31 Mar 24 | 0 | -31 | 10 | 0 |
| 31 Dec 23 | 0 | -30 | 10 | 0 |
| 30 Sep 23 | 0 | -29 | 10 | 15 |
| 30 Jun 23 | 0 | -28 | 9 | 0 |
| 31 Mar 23 | 0 | -29 | 9 | 0 |
| 31 Dec 22 | 0 | -28 | 10 | 0 |
| 30 Sep 22 | 0 | -29 | 10 | 0 |
| 30 Jun 22 | 0 | -30 | 10 | 0 |
| 31 Mar 22 | 0 | -29 | 10 | 0 |
| 31 Dec 21 | 0 | -28 | 10 | 0 |
| 30 Sep 21 | 5 | -22 | 10 | 0 |
| 30 Jun 21 | 10 | -15 | 9 | 0 |
| 31 Mar 21 | 10 | -16 | 9 | 0 |
| 31 Dec 20 | 10 | -16 | 9 | 0 |
| 30 Sep 20 | 5 | -19 | 9 | 0 |
| 30 Jun 20 | 0 | -23 | 10 | 0 |
| 31 Mar 20 | 0 | -21 | 10 | 0 |
| 31 Dec 19 | 7 | -19 | 11 | 0 |
| 30 Sep 19 | 7 | -22 | 12 | 0 |
| 30 Jun 19 | 7 | -27 | 12 | 0 |
| 31 Mar 19 | 7 | -36 | 13 | 0 |
| 31 Dec 18 | 0 | -49 | 13 | 0 |
| 30 Sep 18 | 0 | -55 | 13 | 0 |
| 30 Jun 18 | 0 | -60 | 13 | 0 |
| 31 Mar 18 | 0 | -68 | 13 | 0 |
| 31 Dec 17 | 0 | -72 | 13 | 0 |
| 30 Sep 17 | 0 | -77 | 15 | 0 |
| 30 Jun 17 | 0 | -81 | 17 | 0 |
| 31 Mar 17 | 1 | -81 | 17 | 0 |
| 31 Dec 16 | 1 | -82 | 18 | 0 |
| 30 Sep 16 | 12 | -69 | 19 | 0 |
| 30 Jun 16 | 14 | -63 | 22 | 0 |
| 31 Mar 16 | 17 | -62 | 21 | 0 |
| 31 Dec 15 | 21 | -56 | 19 | 0 |
| 30 Sep 15 | 14 | -71 | 17 | 0 |
| 30 Jun 15 | 13 | -67 | 12 | 0 |
| 31 Mar 15 | 10 | -58 | 12 | 0 |
| 31 Dec 14 | 8 | -57 | 12 | 0 |
| 30 Sep 14 | 9 | -36 | 10 | 0 |
| 30 Jun 14 | 14 | -29 | 9 | 0 |
| 31 Mar 14 | 18 | -24 | 8 | 0 |
| 31 Dec 13 | 20 | -19 | 7 | 0 |
Quality Earnings: RGLS is currently unprofitable.
Growing Profit Margin: RGLS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RGLS is unprofitable, and losses have increased over the past 5 years at a rate of 14.2% per year.
Accelerating Growth: Unable to compare RGLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RGLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RGLS has a negative Return on Equity (-47.96%), as it is currently unprofitable.